Popular Trials
Procedure
Lead Placement for Cardiac Resynchronization in Heart Failure
This trial is testing whether or not placing a lead in the lateral wall of the left ventricle in patients who need cardiac resynchronization therapy affects myocardial function and the severity of mitral regurgitation.
Device
Carillon Device for Heart Failure with Mitral Regurgitation
This trial is testing a device called the Carillon Mitral Contour System, which helps the mitral valve in the heart work better. It targets patients with heart failure and a specific valve problem. The device reshapes the valve to improve its function and reduce symptoms.
Popular Filters
Trials for Left Ventricular Dysfunction Patients
Inorganic Nitrate
Inorganic Nitrate for Heart Failure
This trial is to study the effects of inorganic nitrate on blood pressure, blood nitrate levels, breath nitric oxide levels, and exercise performance, in order to see if it is an effective therapy for heart failure.
Bioprostheses
Edwards Bioprosthetic Heart Valves for Heart Valve Disease
This trial is to confirm that modifications to tissue processing, valve sterilization and packaging do not raise any new questions of safety and effectiveness in subjects who require replacement of their native or prosthetic aortic or mitral valve.
Ventricular Assist Device
Jarvik 2000 VAS for Heart Failure
This trial is testing two different types of devices to see which is better for people with end-stage heart failure. One group will get the Jarvik 2000 LVAS, and the other will get the Thoratec HeartMate II LVAS.
Trials for Right Ventricular Dysfunction Patients
Inorganic Nitrate
Inorganic Nitrate for Heart Failure
This trial is to study the effects of inorganic nitrate on blood pressure, blood nitrate levels, breath nitric oxide levels, and exercise performance, in order to see if it is an effective therapy for heart failure.
Bioprostheses
Edwards Bioprosthetic Heart Valves for Heart Valve Disease
This trial is to confirm that modifications to tissue processing, valve sterilization and packaging do not raise any new questions of safety and effectiveness in subjects who require replacement of their native or prosthetic aortic or mitral valve.
Ventricular Assist Device
Jarvik 2000 VAS for Heart Failure
This trial is testing two different types of devices to see which is better for people with end-stage heart failure. One group will get the Jarvik 2000 LVAS, and the other will get the Thoratec HeartMate II LVAS.
Trials With No Placebo
Inorganic Nitrate
Inorganic Nitrate for Heart Failure
This trial is to study the effects of inorganic nitrate on blood pressure, blood nitrate levels, breath nitric oxide levels, and exercise performance, in order to see if it is an effective therapy for heart failure.
Bioprostheses
Edwards Bioprosthetic Heart Valves for Heart Valve Disease
This trial is to confirm that modifications to tissue processing, valve sterilization and packaging do not raise any new questions of safety and effectiveness in subjects who require replacement of their native or prosthetic aortic or mitral valve.
Ventricular Assist Device
Jarvik 2000 VAS for Heart Failure
This trial is testing two different types of devices to see which is better for people with end-stage heart failure. One group will get the Jarvik 2000 LVAS, and the other will get the Thoratec HeartMate II LVAS.
Physician Payment Models for Heart Conditions
This trial will compare two models for physician payment, one in which physicians are paid a fee for each service provided (fee-for-service), and one in which physicians are given a bonus for meeting quality standards (pay-for-performance). The goal is to see if the pay-for-performance model results in better care for patients with heart conditions.
View More Related Trials
Frequently Asked Questions
Introduction to heart failure
What are the top hospitals conducting heart failure research?
When it comes to advancing the treatment and understanding of heart failure, several top hospitals across the United States are leading the charge. One such institution is Massachusetts General Hospital in Boston. With nine active clinical trials focused on heart failure and an impressive 99 all-time trials dedicated to this condition, their commitment to research is evident. Since recording their first heart failure trial in 2001, they have been at the forefront of groundbreaking discoveries and innovative treatments. Northwestern University in Chicago also plays a vital role in shaping the future of heart failure care, with six ongoing trials and 46 completed studies since their inaugural trial in 2003.
Meanwhile, Cleveland Clinic in Ohio has established itself as a hub for cutting-edge cardiac research as well. With six active clinical trials focused on heart failure and an accumulated record of 63 previously conducted studies dating back to their first recorded trial in 2005, they continue to make significant contributions to this field. Yale University Medical Center located in New Haven boasts similar figures, with six current investigations into heart failure treatment options and a history that includes 21 past clinical trials since initiating their pioneering study on this condition back in 2002.
Last but not least we find ourselves at Medical University of South carolina situated within Charleston where they too contribute towards improving our understanding about Heart failures; keeping up actively through maintaining approximately six contemporary experiments while playing part conducting over fifty-three previous inquiries which started way before from initial test being held sometime around2011.These respective hospitals serve as beacons of hope for individuals affected by heart failure worldwide; through these trials new treatments can be developed thus improving patient outcomes significantly.
The tireless efforts made by these esteemed medical institutions highlight both the significance placed upon tackling cardiovascular diseases like chronic congestive conditionsand renewed sense regarding human beings endeavoring altogether towards healthier lives for everyone
Which are the best cities for heart failure clinical trials?
When it comes to heart failure clinical trials, several cities stand out as hubs for research and advancement. New york leads the way with 30 active trials exploring treatments such as Edwards Aortic and Mitral Bioprostheses Models 11000A and 11000M, MitraClip System, Investigational LUX-Dx ICM Implant, among others. Philadelphia follows closely with 20 ongoing studies focused on innovative approaches like Cardiac Contractility Modulation Therapy via OPTIMIZERâ„¢ Smart Mini System and the MitraClip System. Saint Louis also plays a significant role in heart failure research, with 19 active trials studying various treatments including Device and Medical Management and BATwire Implant Kit. These cities offer individuals battling heart failure access to cutting-edge clinical trials that drive progress towards better treatment options and improved outcomes.
Which are the top treatments for heart failure being explored in clinical trials?
Clinical trials are actively exploring potential treatments for heart failure, with two frontrunners emerging. Vericiguat is currently involved in two ongoing trials dedicated to studying its efficacy in treating this condition. Since its introduction in 2016, it has been a part of five all-time heart failure trials, indicating promising results. Another contender is "Usual Care," which also boasts participation in two active trials and has been studied in 27 all-time heart failure clinical trials since 2001. These treatments hold significant promise as researchers strive to find innovative solutions for patients battling heart failure.
What are the most recent clinical trials for heart failure?
Exciting advancements in heart failure research offer hope for those affected by this condition. Recent clinical trials have explored various interventions, such as the implementation of an intervention group specifically designed to address heart failure. Additionally, the effectiveness of medications like empagliflozin and vericiguat has been investigated through rigorous testing in multiple phases. Promising results have emerged from these studies, showcasing their potential benefits for individuals battling heart failure. Another notable trial focused on ziltivekimab at a dosage of 15 mg, aiming to evaluate its efficacy in treating this condition. With ongoing research and innovative approaches being explored, there is optimism that improved treatment options will soon be available for patients with heart failure.
What heart failure clinical trials were recently completed?
Recent advancements in heart failure research have seen the completion of several notable clinical trials. In September 2021, Pfizer concluded a trial investigating the potential benefits of Prazosin HCl 2mg for managing this challenging condition. Similarly, Ionis Pharmaceuticals wrapped up their IONIS-AGT-LRx study in June 2021, while scPharmaceuticals completed their Furoscix Infusor trial in May 2021. These significant milestones were preceded by Novo Nordisk A/S's investigation into Semaglutide, which finished in March 2021, and Mayo Clinic's exploration of Dapagliflozin that concluded in February 2021. Collectively, these studies contribute to our understanding of heart failure treatment options and offer hope for improved outcomes among patients dealing with this debilitating disease.